Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 15, 2023

SELL
$4.2 - $6.01 $15 Million - $21.4 Million
-3,565,711 Reduced 22.28%
12,437,278 $52.2 Million
Q4 2022

Feb 14, 2023

BUY
$4.45 - $6.17 $10.1 Million - $13.9 Million
2,260,435 Added 16.45%
16,002,989 $96.2 Million
Q3 2022

Nov 15, 2022

BUY
$5.36 - $7.43 $20.9 Million - $28.9 Million
3,893,026 Added 39.53%
13,742,554 $80 Million
Q2 2022

Aug 15, 2022

BUY
$3.55 - $6.27 $34 Million - $60.1 Million
9,578,193 Added 3530.02%
9,849,528 $58.8 Million
Q1 2022

May 16, 2022

BUY
$1.9 - $5.23 $110,239 - $303,449
58,021 Added 27.2%
271,335 $1.27 Million
Q3 2021

Nov 15, 2021

BUY
$2.25 - $3.18 $107,775 - $152,322
47,900 Added 28.96%
213,314 $629,000
Q2 2021

Aug 16, 2021

BUY
$2.16 - $2.62 $311,605 - $377,966
144,262 Added 682.03%
165,414 $414,000
Q1 2021

May 17, 2021

BUY
$2.68 - $3.8 $8,308 - $11,780
3,100 Added 17.17%
21,152 $62,000
Q1 2020

May 11, 2020

BUY
$0.69 - $1.54 $12,455 - $27,800
18,052 New
18,052 $17,000

About CTI BIOPHARMA CORP


  • Ticker CTIC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 114,385,000
  • Market Cap $1.04B
  • Description
  • CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients w...
More about CTIC
Track This Portfolio

Track State Street Corp Portfolio

Follow State Street Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

News

Stay updated on State Street Corp with notifications on news.